# Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

> **NCT06411210** · PHASE2 · RECRUITING · sponsor: **Yale University** · enrollment: 54 (estimated)

## Conditions studied

- Diabetes type1
- Obesity

## Interventions

- **DRUG:** Semaglutide Pen Injector
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06411210
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-16
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411210, "Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06411210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*